1. Scrip
  2. >>Therapy Areas

Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It

Debate At CTAD Underscores Doctors’ Dilemma

 
• By Mandy Jackson

The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.

Doctor viewing patient's brain scan on digital tablet in laboratory
Academic doctors may be able to inform initial Aduhelm treatment decisions • Source: Alamy

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting conceded that the mixed Phase III results for Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (aducanumab) complicate decisions about whether to prescribe the drug. However, they also suggested that Aduhelm as is the first and only potentially disease-modifying therapy approved in the US for Alzheimer’s disease, ongoing debates around safety and efficacy should not prevent doctors from trying the medicine in patients with no other options.

A 9 November roundtable discussion of the US Food and Drug Administration’s accelerated approval of Aduhelm in June underscored the ongoing dilemma that prescribers face. (Also see "Biogen/Eisai Win...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.